Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wesley Jessen Seeks Sweetened Acquisition Offer From Bausch & Lomb

This article was originally published in The Gray Sheet

Executive Summary

Bausch & Lomb can afford to increase its offer to buy tinted contact lens manufacturer Wesley Jessen by up to $8 a share without diluting earnings per share for 2001 and 2002, Wesley Jessen told shareholders in an April 10 letter advising them to reject Bausch & Lomb's unsolicited $34 bid. Bausch & Lomb's hostile tender offer commenced April 3.

You may also be interested in...



Wesley Jessen Looks For White Knight To Top Bausch & Lomb Acquisition Bid

Wesley Jessen's decision to enter discussions with other potential suitors apparently has forced Bausch & Lomb to sweeten its offer in the hostile takeover bid for the specialty contact lens company.

Wesley Jessen Looks For White Knight To Top Bausch & Lomb Acquisition Bid

Wesley Jessen's decision to enter discussions with other potential suitors apparently has forced Bausch & Lomb to sweeten its offer in the hostile takeover bid for the specialty contact lens company.

B&L Looking To Enter Cosmetic Lens Market Via Wesley Jessen Acquisition

Bausch & Lomb's unsolicited offer for cosmetic contact lens manufacturer Wesley Jessen VisionCare will have to take into account a $20 mil. one-time charge the latter will face if it walks away from a previously announced definitive merger agreement with Ocular Sciences.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel